Mankind Pharma share price
NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,275.60.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹91,390 Cr119th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 44.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 5.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 12.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.38
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,79,10661.7% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 30 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,031 Crup 17.07%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹574 Crup 2.62%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 14.2%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 5 Nov | Dec 2024Filed 24 Jan | Mar 2025Filed 25 Jun | Jun 2025Filed 31 Jul | Sep 2025Filed 6 Nov | Dec 2025Filed 3 Feb | Mar 2026Filed 19 May | Jun 2026Filed 30 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,077 | 3,230 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| Net profit | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 21.4% | 11.9% | 13.8% | 12.5% | 14.1% | 11.6% | 16.2% | 14.2% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 6% of 669 trading days since Feb 2024.
At or below today's level on 3% of 744 trading days over the last 3 years.
At or below today's level on 0.2% of 669 trading days since Feb 2024.
At or below today's level on 67% of 744 trading days over the last 3 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −17.2% | −5.9% | −12.0% | 0.0% |
Mutual funds holding it
226 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 89 of the 122 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 66
- CutCut. Funds that held fewer shares than at the end of the month before.
- 56
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 96
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 11
| Fund | |||
|---|---|---|---|
 SBI Large Cap FundSBI Mutual Fund | 40,72,930 | 1.95% | ₹1,019.8 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 39,00,000 | 1.95% | ₹976.5 Cr |
 HDFC Large Cap FundHDFC Mutual Fund | 27,39,492 | 1.84% | ₹685.9 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 21,34,592 | 1.04% | ₹534.5 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 20,72,385 | 1.85% | ₹518.9 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 16,03,562 | 4.38% | ₹401.5 Cr |
 Franklin India Opportunities FundFranklin Templeton Mutual Fund | 15,21,556 | 3.98% | ₹381.0 Cr |
| Aditya Birla Sun Life Large Cap FundAditya Birla Sun Life Mutual Fund | 15,10,424 | 1.35% | ₹378.2 Cr |
 HSBC Midcap FundHSBC Mutual Fund | 14,92,496 | 2.22% | ₹373.7 Cr |
 Mirae Asset Midcap FundMirae Asset Mutual Fund | 14,31,251 | 1.83% | ₹358.4 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Mankind Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 8 Aug 2025 | Interim | ₹1.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Analysts
22 Oct · Analysts
15 Oct · Board meeting
12 Oct · Analysts
Mankind Pharma share price by year
Each calendar year to 2025.Mankind Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,196.50 | −23.7% | 2,937.55 | 2,106.00 |
| 2024 | 2,880.40 | +45.3% | 2,998.40 | 1,979.20 |
| 2023 | 1,982.50 | – | 2,012.90 | 1,322.65 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2,282.90 | 2,289.60 | 2,196.10 | 2,212.60 | 2,219.19 | 6,79,106 | 61.7% |
| 22 Oct 2026 | 2,266.00 | 2,299.60 | 2,233.60 | 2,275.60 | 2,263.23 | 6,49,740 | 52.8% |
| 21 Oct 2026 | 2,256.20 | 2,285.50 | 2,243.10 | 2,285.50 | 2,258.45 | 2,46,631 | 57.3% |
| 19 Oct 2026 | 2,264.10 | 2,348.50 | 2,246.00 | 2,253.20 | 2,288.79 | 12,28,705 | 59.9% |
| 16 Oct 2026 | 2,349.90 | 2,354.40 | 2,268.70 | 2,275.50 | 2,289.28 | 8,89,731 | 61.7% |
| 15 Oct 2026 | 2,325.60 | 2,365.00 | 2,321.10 | 2,347.60 | 2,353.57 | 6,45,492 | 61.4% |
| 14 Oct 2026 | 2,372.00 | 2,372.00 | 2,317.50 | 2,335.00 | 2,335.36 | 4,98,158 | 59.1% |
| 13 Oct 2026 | 2,400.00 | 2,401.10 | 2,356.20 | 2,372.00 | 2,372.97 | 3,29,114 | 68.9% |
| 12 Oct 2026 | 2,368.50 | 2,426.80 | 2,368.50 | 2,400.00 | 2,403.20 | 2,05,896 | 53.3% |
| 9 Oct 2026 | 2,380.00 | 2,389.80 | 2,342.00 | 2,368.50 | 2,369.78 | 3,06,899 | 47.5% |
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company with its registered office in New Delhi. It sells medicines prescribed by doctors and consumer healthcare products that people buy over the counter. It was incorporated in 1991.
The business is organised in four parts: Mass Market, Specialty Chronic, Consumer Healthcare (OTC) and BSV Super Specialty. Its revenue comes from domestic sales and from an exports business. Its prescription medicines cover therapy areas such as cardiovascular, anti-diabetic, gynaecology, gastro-intestinal and anti-infectives. In consumer healthcare, its brands include Manforce, Prega News and Gas-o-fast. It runs 32 manufacturing facilities and has more than 27,000 employees. It has seven research and development centres and more than 17,600 stockists. It has filed 76 ANDAs in the United States, which are applications to sell generic medicines there.
The company entered consumer healthcare by launching the Manforce and Prega News brands. Later it acquired brands from Panacea, signed in-licensing agreements with companies including Novartis and Takeda, and acquired 100% of BSV Limited, whose results are included from 23 October 2024. BSV Limited has added to its presence in women's health, fertility and critical care. Its shares are listed on the NSE and the BSE.
Ramesh Juneja is the company's founder and executive chairman. Rajeev Juneja, its vice chairman and managing director, is one of its promoters. A promoter is the person or group that set up a company or controls it.
- Legal name
- Mankind Pharma Limited
- NSE symbol
- MANKIND
- BSE code
- 543904
- ISIN
- INE634S01028
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 2023
- Face value
- ₹1
- CIN
- L74899DL1991PLC044843
- Corporate identity number, the registrar of companies' code for it